Concepedia

Thomas Idorn

TI

27

Publications

3.3K

Citations

21

H-Index

2010

Active since

Affiliations

University of Copenhagen(Current)

Novo Nordisk (Denmark)

Rigshospitalet

Steno Diabetes Centers

Friedrich-Alexander-Universität Erlangen-Nürnberg

Thomas Idorn is an author at University of Copenhagen specializing in medicine, chronic kidney disease, and diabetes.

Top concepts

Publications per year

2010–2024

27

Publications

27

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

Vlado Perkovic, Katherine R. Tuttle, Peter Rossing et al. · New England Journal of Medicine · 2024 · 1.2K citations

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Ahmed M. Shaman, Stephen C. Bain, George L. Bakris et al. · Circulation · 2021 · 225 citations · Full text

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Peter Rossing, Florian M.M. Baeres, George L. Bakris et al. · Nephrology Dialysis Transplantation · 2023 · 221 citations · Full text

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

Nicolai J. Wewer Albrechtsen, Bolette Hartmann, Simon Veedfald et al. · Diabetologia · 2014 · 183 citations · Full text

, , +6

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Helen M. Colhoun, Ildiko Lingvay, Paul Brown et al. · Nature Medicine · 2024 · 168 citations · Full text

Rows per page

1–5 of 27